TAG:
infectious disease testing
New Report: POC Market Will Grow 30% by 2013
By Robert Michel | From the Volume XVI No. 7 – May 18, 2009 Issue
CEO SUMMARY: It will be no surprise to lab directors and pathologists that Kalorama Information, in its latest report on point-of-care (POC) testing, estimates that glucose testing comprises 67% of this market segment. What is notable is Kalorama’s prediction that worldwide POC…
Labs Need to Respond To Inaccurate Results
By Robert Michel | From the Volume XVI No. 1 – January 12, 2009 Issue
CEO SUMMARY: What does a lab do when it discovers that it has reported inaccurate test results? In 2004, a turnaround team arrived at the laboratory of Maryland General Hospital in Baltimore to deal with the consequences of a failed infectious disease testing program. For about t…
Hospital Labs Have New Options for Molecular Dx
By Robert Michel | From the Volume XV No. 14 – October 20, 2008 Issue
CEO SUMMARY: Laboratories that offer molecular assays continue to see strong growth in four areas: oncology, hematopathology, infectious diseases, and personalized medicine. Further, a new generation of molecular testing systems and analyzers is coming to market which will make it easier …
BRLI Seizes NYC Share In Two-Stage Effort
By Robert Michel | From the Volume XIV No. 10 – July 16, 2007 Issue
CEO SUMMARY: Bio-Reference Laboratories, Inc., (BRLI) reported record financial results for its most recent fiscal quarter last month. Much of this success is rooted in BRLI’s discipline in defining itself as a local laboratory and using enhanced lab testing services to align itself as …
Key Trends Drive Change for Clinical Laboratories
By Robert Michel | From the Volume XIV No. 1 – January 8, 2007 Issue
CEO SUMMARY: Technology plays an ever-growing role in reshaping the organization and operation of clinical laboratories. New technologies figure prominently in THE DARK REPORT’S 2007 list of key trends in the clinical laboratory industry. Technological advances in instr…
Luminex and PerkinElmer Ink Licensing Agreement
By Robert Michel | From the Volume XIII No. 1 – January 16, 2006 Issue
CEO SUMMARY: PerkinElmer’s interest in the multiplex capabilities of Luminex’s xMap technology led to this new licensing agreement. PerkinElmer’s instrument systems played a major role in accelerating the work of the Human Genome Project. Now, besides bioresearch applications, Perki…
For Molecular Tests, Evaluate All Factors
By Robert Michel | From the Volume XII No. 8 – May 30, 2005 Issue
CEO SUMMARY: When this hospital lab adopted molecular screening tests for Chlamydia trachomatis and Neisseria gonorrhoaea, physicians soon noticed a change in the rate of false positives. In researching the performance of the molecular assays compared to cultures, pathologists at this lab…
“May 9, 2005 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XII No. 7 – May 9, 2005 Issue
Tight-lipped executives at Meridian Bioscience, Inc. have yet to speak in public on any aspect of how live H2N2 influenza virus found its way into the virology proficiency test kits it shipped to thousands of labs on behalf of four lab proficiency testing organizations. Meridian, bas…
New Esoteric Lab Firm Does Two Acquisitions
By Robert Michel | From the Volume XI No. 6 – April 26, 2004 Issue
CEO SUMMARY: Armed with $70 million, American Esoteric Laboratories (AEL) wants to build a national laboratory that offers a full menu of esoteric tests. It is building a primary laboratory in Dallas, which has one of the nation’s best air transport hubs. ThromboCare Laboratories and Vi…
Eritrea Uses St. Louis For Reference Testing
By Robert Michel | From the Volume X No. 6 – May 5, 2003 Issue
CEO SUMMARY: On one level, it’s the classic story of volunteerism and help for a developing nation. But on another level, it’s a dramatic demonstration of how new technologies allow two hospital laboratories in St. Louis, Missouri to effectively provide reference laboratory tests and …
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized